The effect of microdosing have been overstated, at least when it comes to depression.

A Phase 2B trial of 89 adult patients conducted by Melbourne-based MindBio Therapeutics, investigating the effects of microdosing LSD in the treatment of major depressive disorder, found that the psychedelic was actually outperformed by a placebo. Across an eight-week period, symptoms were gauged using the Montgomery-Åsberg Depression Rating Scale (MADRS), a widely recognized tool for the clinical evaluation of depression.

The study has not yet been published. But MindBio’s CEO Justin Hanka recently released the top-line results on his LinkedIn, eager to show that his company was “in front of the curve in microdosing research.”

  • Bademantel@lemmy.worldEnglish
    17·
    2 days ago

    Really? I associate it with LSD. Isn’t it more difficult with mushrooms as psilocybin concentration fluctuates? I guess you could extract it. Never really thought about it.

    • nullroot@lemmy.worldEnglish
      6·
      2 days ago

      Grind it up and put it in pills. The resulting pills will have approximately the same doses

    • Beacon@fedia.io
      6·
      2 days ago

      The fluctuation doesn’t make enough difference to switch between a microdose to a macrodose. But don’t depend on the shake scraps at the bottom of the bag, because that stuff actually can vary wildly